Wednesday, February 10, 2010, 6:36am EST - Canadian Markets open in 2 hours and 54 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Repligen Corp. (RGEN)

 On Feb 9: 3.40 USD   0.00 (0.00%)  
MORE ON RGEN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Repligen Corporation (NGM:RGEN) Delayed quote dataEdit
Last Trade: 3.40 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 3.40
Open: N/A
Bid: 3.02 x 100
Ask: 4.99 x 200
1y Target Est: 8.00
Day's Range: N/A - N/A
52wk Range: 3.35 - 5.85
Volume: 0
Avg Vol (3m): 121,895
Market Cap: 104.58M
P/E (ttm): 2.59
EPS (ttm): 1.31
Div & Yield: N/A (N/A%)
Repligen Corp. (RGEN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add RGEN to Portfolio   Download Data

HEADLINES
• 3 Stocks Hitting Low Notes
at Motley Fool (Thu, Feb 4)
• Repligen Corporation F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
at Seeking Alpha (Thu, Feb 4)
• REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Thu, Feb 4)
• Repligen Reports Third Quarter Fiscal Year 2010 Financial Results
PRNewswire (Thu, Feb 4)
• Q3 2010 Repligen Corporation Earnings Release - Before Market Open
CCBN (Thu, Feb 4)
• REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Ag
EDGAR Online (Wed, Feb 3)
• Repligen Receives Notice of Allowance for Recombinant Protein A Patent
PRNewswire (Wed, Feb 3)
• Repligen to Present at the BIO CEO & Investor Conference Monday, February 8th, 2:00 p.m. EST
PRNewswire (Mon, Feb 1)
• Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST
PRNewswire (Fri, Jan 29)
• 4 Stocks That Laugh at Wall Street
at Motley Fool (Thu, Jan 28)
More Headlines for RGEN...
ANALYST
EPS Est (next year) (Mar-08) : N/A
EPS Est (in 2 years) (Mar-09) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Repligen Corporation, a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices